Continuous intravenous vancomycin in children with normal renal function hospitalized in hematology-oncology:...

Area of Science:

• Pediatric pharmacology
• Infectious disease pharmacotherapy
• Oncology and hematology therapeutics

Background:

• Continuous intravenous vancomycin infusion is optimal due to time-dependent bactericidal activity.
• Current pediatric dosing guidelines often fail to achieve target vancomycin serum concentrations (15-20 mg/L) in patients with normal renal function.
• Pediatric oncology-hematology patients require optimized vancomycin dosing for effective treatment.

Purpose of the Study:

• To prospectively validate an age-based vancomycin dosing nomogram in pediatric oncology-hematology patients.
• To assess the influence of patient-specific variables on achieving target vancomycin serum concentrations.

Main Methods:

• Retrospective analysis of Bayesian dosing adjustments in 161 patients (2000-2010) to create an age-based nomogram.
• Prospective validation of the nomogram in 94 pediatric patients (4.3 months to 17.9 years) with normal renal function.
• Evaluation of factors including age, gender, underlying disease (oncology/hematology), and prior hematopoietic stem cell transplantation (HSCT).

Main Results:

• Prospective validation demonstrated that 58.5% of patients achieved the target vancomycin serum concentration range.
• No significant differences in target attainment were observed across age groups or by gender.
• A trend towards better target attainment was noted in oncology patients and those who had not undergone HSCT.

Conclusions:

• The prospectively validated age-based vancomycin nomogram helps achieve target serum concentrations in approximately 60% of pediatric oncology-hematology patients.
• This nomogram provides a valuable tool for optimizing vancomycin therapy in this specific pediatric population.
• Further investigation into factors influencing vancomycin Css attainment may refine dosing strategies.